The Recall Desk

Recalls

All US Product Recalls

Searchable archive of product recalls from the FDA, USDA FSIS, CPSC, NHTSA, and EPA — translated into plain English, severity-scored from objective criteria, and always linked back to the original government notice.

How to read this listing

Every recall on this list has been scored 1–5 against an objective rubric from the agency’s own classification, presence of reported injuries or deaths, distribution scope, and hazard type. The colored severity badge on each card is the score — 5 (Critical) means the agency’s own highest classification or reported deaths or serious injuries, 4 (Severe) means significant injury or hospitalization risk, and 3 (High) means a known hazard with no confirmed harm yet. Filter to 3+ (High and above) if you want to skip routine Class-III notices.

The agency chips above control which streams are visible. FDA spans food, drugs, and medical devices. USDA FSIS is meat, poultry, and processed egg products. CPSC is household consumer products. NHTSA is vehicles, tires, and child seats. Nationwide on a card means the recall affects every US state — most do — while a state list means distribution was limited.

Click any recall to see the full summary, affected lot codes and model numbers, the agency’s own classification, and a direct link back to the original government notice for verification.

Filters

Agency

Category

Minimum severity

Clear filters

13826–13850 of 17799

  • SevereFDA (Drugs)·D-887-2015·2015-04-29

    Attix Pharmaceuticals Recalls Satraplatin Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Satraplatin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Satraplatin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-711-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hydralazine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Hydralazine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Hydralazine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-756-2015·2015-04-29

    Attix Pharmaceuticals Recalls Levocetirizine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Levocetirizine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Levocetirizine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-511-2015·2015-04-29

    Attix Pharmaceuticals Recalls Amikacin Sulfate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Amikacin Sulfate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Amikacin Sulfate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-834-2015·2015-04-29

    Attix Pharmaceuticals Recalls Paroxetine HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Paroxetine HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Paroxetine HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-867-2015·2015-04-29

    Progesterone API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling progesterone active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Progesterone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-611-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dantrolene Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Dantrolene Sodium API lots distributed between January 2012 and February 2015 due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Dantrolene Sodium (Light Yellow) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-500-2015·2015-04-29

    Attix Pharmaceuticals Recalls Acetylsalicyclic Acid Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling acetylsalicyclic acid active pharmaceutical ingredient due to potential penicillin cross-contamination. The product was distributed to compounding pharmacies and research organizations.

    Product
    Acetylsalicyclic acid active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-0969-2015·2015-04-29

    Hospira Recalls 0.9% Sodium Chloride Injection Due to Human Hair Particulate

    Hospira is recalling 0.9% Sodium Chloride Injection, USP, 250 mL, because a human hair was found sealed in the bag at the additive port area.

    Product
    0.9% Sodium Chloride Injection, USP, 250 mL, Rx Only, Hospira Inc., Lake Forest, IL, 60045, USA, NDC 0409-7983-02
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-694-2015·2015-04-29

    Attix Pharmaceuticals Recalls Furazolidine Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Furazolidine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Furazolidine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-874-2015·2015-04-29

    Attix Pharmaceuticals Recalls Quinine Sulfate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Quinine Sulfate Dihydrate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Quinine Sulfate Dihydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-706-2015·2015-04-29

    Attix Pharmaceuticals Recalls Histamine Phosphate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Histamine Phosphate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Histamine Phosphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-589-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cisatracurium Besylate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cisatracurium Besylate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Cisatracurium Besylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-665-2015·2015-04-29

    Attix Pharmaceuticals Recalls Etomidate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Etomidate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Etomidate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-586-2015·2015-04-29

    Attix Pharmaceuticals Recalls Cimetidine API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Cimetidine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Cimetidine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-653-2015·2015-04-29

    Attix Pharmaceuticals Recalls Estradiol Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Estradiol (Micronized) active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Estradiol (Micronized) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-683-2015·2015-04-29

    Fluorexon API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Fluorexon active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Fluorexon active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-953-2015·2015-04-29

    Attix Pharmaceuticals Recalls Vidarbine Monophosphate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Vidarbine Monophosphate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Vidarbine Monophosphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-930-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tiopronin Base Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tiopronin Base active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Tiopronin Base active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-906-2015·2015-04-29

    Attix Pharmaceuticals Recalls Sulfanilamide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Sulfanilamide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Sulfanilamide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-718-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hydroxocobalamin Acetate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Hydroxocobalamin Acetate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Hydroxocobalamin Acetate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-556-2015·2015-04-29

    Attix Pharmaceuticals Recalls Calcitriol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling calcitriol active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Calcitriol active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-606-2015·2015-04-29

    Cyclophosphamide Monohydrate Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Cyclophosphamide Monohydrate active pharmaceutical ingredient due to potential penicillin cross contamination during repackaging.

    Product
    Cyclophosphamide Monohydrate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-764-2015·2015-04-29

    Linezolid API Recalled for Potential Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling Linezolid active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Linezolid active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-883-2015·2015-04-29

    Attix Pharmaceuticals Recalls Rocuronium Bromide Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Rocuronium Bromide active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Rocuronium Bromide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide